This content is from:365亚博 Drug Wars: The Battle to Put a Lid on Rising Prices In the first of five stories on the battle to address skyrocketing drug prices in the U.S., Institutional Investor looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington. ByKhadijah M. Silver November 25, 2015
This content is from:365亚博 Pharmaceutical Companies Gird for Drug-Price Reckoning Uproar over suddenly hiked-up medications may not crush health care stocks for long, but it does force the industry to justify value. ByKaitlin Ugolik October 08, 2015
This content is from:365亚博 Hedge Fund Manager Kyle Bass Declares War on Drug Prices Through his Coalition for Affordable Drugs, Bass is challenging pharmaceuticals companies’ patents and shorting their stocks. ByJess Delaney October 22, 2015
This content is from:365亚博 Health Care Loans Offer Possible Remedy for High U.S. Drug Costs MIT finance professor Andrew Lo thinks securitized loans could make livesaving therapies more accessible, but there are potential risks. ByBailey McCann March 18, 2016
This content is from:365亚博 The Race to Rein in U.S. Drug Prices The fifth and final story in our series on escalating U.S. drug prices looks at the impact that presidential politics will have on the pharma industry. ByKhadijah M. Silver February 11, 2016
This content is from:365亚博 The Morning Brief: Marshall Wace Co-Founder Backs Controversial Plan ByAmanda Cantrell September 24, 2015
